ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Very high–power short-duration radiofrequency ablation in patients with typical atrial flutter: rationale and design of the FASD-HP randomized trial

  • 期刊论文

  • 发表日期：

    2024年12月21日

查看全文
  • Laura Valverde Soria,
  • Jorge Toquero,
  • Thomas Brouzet,
  • Laura García Cano,
  • Ana García Barrios,
  • Melodie Segura Domínguez,
  • Gloria A. Hermón Ramírez,
  • Raquel Ajo Ferrer,
  • María Ajo Ferrer,
  • Celia María Andreu Concha,
  • Vicente Arrarte Esteban,
  • Angel Sánchez Barbié,
  • Juan Gabriel Martínez-Martínez,
  • Alicia Ibáñez Criado,
  • José Luis Ibáñez Criado

摘要

Background

The aim of cavotricuspid isthmus (CTI)-dependent flutter ablation is the bidirectional conduction block of the CTI. Very-high–power short-duration (vHPSD) radiofrequency ablation aims to minimize conductive heating and increase resistive heating to create shallower but wider lesions in a very short time, while reducing the risk of collateral tissue damage. Experimental studies have shown that it produces effective transmural lesions with an equal or better safety profile compared to conventional parameters. There are published and ongoing trials studying long-term outcomes of this technique for pulmonary vein isolation, but there is a lack of evidence regarding its use in flutter ablation.

Methods and results

Multicenter 1:1 randomized, single-blind study. Two CTI ablation strategies are compared: (1) conventional treatment arm consisting of 25–40-W applications of unlimited duration until reaching the minimum value of one of the currently accepted lesion markers (Ablation Index > 500 at the anterior half of the CTI and > 400 at the posterior half with CARTO3 system); (2) experimental treatment arm consisting of CTI block using point-by-point applications of very-high–power (90 W) short duration (4 s). The primary objective is to evaluate the non-inferiority of the efficacy and safety of vHPSD ablation in patients undergoing typical flutter ablation. Secondary objectives include comparison of total radiofrequency time, number of applications, number of steam pops, percentage of reconnections, procedure duration, pain during the procedure, and time to flutter recurrence.

Conclusions

The FASD-HP trial is the first clinical trial to investigate the non-inferiority of CTI ablation with vHPSD in patients with typical atrial flutter.

Clinical Trial Registration number

The study was registered at http://www.clinicaltrials.gov (NCT05777850) on March 21, 2023.

Graphical Abstract